Li-ke Qu

Beijing Cancer Hospital, Peping, Beijing, China

Are you Li-ke Qu?

Claim your profile

Publications (3)3.53 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Combinations of multiple biomarkers representing distinct aspects of metastasis may have better prognostic value for breast cancer patients, especially those in late stages. In this study, we evaluated the protein levels of N-α-acetyltransferase 10 protein (Naa10p), synuclein-γ (SNCG), and phosphatase of regenerating liver-3 (PRL- 3) in 365 patients with breast cancer by immunohistochemistry. Distinct prognostic subgroups of breast cancer were identified by combination of the three biomarkers. The Naa10p+SNCG-PRL-3- subgroup showed best prognosis with a median distant metastasis-free survival (DMFS) of 140 months, while the Naa10p-SNCG+PRL-3+ subgroup had the worst prognosis with a median DMFS of 60.5 months. Multivariate analysis indicated Naa10p, SNCG, PRL-3, and the TNM classification were all independent prognostic factors for both DMFS and overall survival (OS). The three biomarker combination of Naa10p, SNCG and PRL-3 performed better in patients with lymph node metastasis, especially those with more advanced tumors than other subgroups. In conclusion, the combined expression profile of Naa10p, SNCG and PRL-3, alone or in combination with the TNM classification system, may provide a precise estimate of prognosis of breast cancer patients.
    Asian Pacific journal of cancer prevention: APJCP 01/2015; 16(7):2819-26. · 2.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HIWI is a member of PIWI gene family and its expression is found in various tumors, indicating that it may play a pivotal role in tumor development. This study was designated to examine HIWI protein expression profile in several cancer cell lines and its prognostic value for patients with colorectal cancer. Totally 270 patients who underwent surgical resection of primary colorectal cancer between January 1999 and December 2002 with a median follow-up time of 33 months were registered in the study. Formalin-fixed and paraffin-embedded specimens from these patients and 236 matched adjacent non-cancerous normal colorectal tissues were collected. Anti-HIWI monoclonal antibodies were generated and used for evaluating HIWI protein expression. χ(2) tests were conducted to determine the association between HIWI expression and the other variables. Survival curves were estimated using the Kaplan-Meier method and compared by the log-rank test. Multivariate analysis was performed by using the Cox regression model. By generating antibodies specific for HIWI, we examined HIWI protein expression in several cancer cell lines and demonstrated positive expression of HIWI in 69 out of 270 (25.6%) colorectal cancer tissues; 15 of 236 (6.4%) matched adjacent non-cancerous tissues were also positive for HIWI. Patients with positive HIWI expression in adjacent non-cancerous tissue had statistically lower overall survival (OS) and disease free survival (DFS) compared with negative patients (OS: 10.4% vs. 55.5%, P = 0.009; DFS: 10.4% vs. 55.1%, P = 0.015). For early stage group (stages I and II), patients with positive HIWI expression had significantly lower OS and DFS (OS: 57.4% vs. 79.5%, P = 0.014; DFS: 56.7% vs. 80.5%, P = 0.010). In lymph node negative group, patients with positive HIWI expression had statistically lower OS and DFS (OS: 53.0% vs. 73.5%, P = 0.037; DFS: 52.2% vs. 74.6%, P = 0.025). Multivariate analysis revealed that HIWI over-expression was a significant prognostic factor for OS (95%CI: 1.132 - 2.479, P = 0.010). HIWI could be a potential prognostic biomarker for the patients with colorectal cancer, especially for those at early stages or without lymph node metastasis.
    Chinese medical journal 07/2011; 124(14):2144-9. DOI:10.3760/cma.j.issn.0366-6999.2011.14.012 · 1.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To construct PRL-3 gene C104S point mutation and CAAX deletion mutants: pcDNA3-myc-PRL-3 (C104S), pEGFP-PRL-3 (C104S), pcDNA3-myc-PRL-3 (DeltaCAAX) and pEGFP-PRL-3 (DeltaCAAX), and express these plasmids in eukaryotic cells. Recombinant plasmids were mutated with pcDNA3-myc-PRL-3 plasmid as template and specific primers. Mutants were identified by restriction enzyme digestion and DNA sequencing. Then these recombinant plasmids were transfected into LoVo cells. The expression of fusion proteins were detected by western blotting and the localization of fusion proteins were examined by GPF fluorescence labelling. The mutants were successfully constructed and expressed in eukaryotic cells. PRL-3 (DeltaCAAX) relocates from plasma membrane/early endosome to the cytoplasm and/or nucleus, which provides a structural insight of PRL-3 protein. Construction of eukaryotic expression recombinant plasmids of PRL-3 gene C104S point mutation and CAAX deletion mutants provide a useful tool for the study of PRL-3's role in cancer.
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 10/2009; 41(5):516-20.